OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Kelly on the Treatment and Heterogeneity of GIST

August 7th 2024

Ciara Kelly, MBBCh, BAO, discusses how the heterogeneity of GIST affects treatment decisions and the importance of testing for genetic abnormalities.

Dr Lentzsch on Results for Linvoseltamab in Heavily Pretreated R/R Myeloma

August 7th 2024

Suzanne Lentzsch, MD, PhD discusses data for linvoseltamab in patients with relapsed/refractory multiple myeloma

Dr Hamilton on Implications of DESTINY-Breast06 on the HER2-Low Breast Cancer Paradigm

August 7th 2024

Erika P. Hamilton, MD, discusses the efficacy of trastuzumab deruxtecan in patients with HER2-low breast cancer.

Dr Bekaii-Saab on the Benefits of Multidisciplinary Conferences in GI Cancer Care

August 7th 2024

Tanios Bekaii-Saab, MD, FACP, discusses the benefits of multidisciplinary conferences within the gastrointestinal cancer treatment field.

Dr Tolaney on Ongoing Clinical Trials in Early-Stage HER2+ Breast Cancer

August 6th 2024

Sara M. Tolaney, MD, MPH discusses ongoing clinical trials investigating the addition of HER2-directed therapies to existing treatment regimens for HER2-positive breast cancer.

Dr Ramsey on Signs and Symptoms of Pneumonitis in Locally Advanced NSCLC

August 6th 2024

Meghan Ramsey, MD, discusses signs and symptoms of pneumonitis in locally advanced non–small cell lung cancer.

Dr Danilov on the Importance of Using BTK as a Target in CLL Treatment

August 6th 2024

Alexey Danilov, MD, PhD, discusses the importance of using BTK as a target, as well as recent updates on BTK degraders within the CLL treatment paradigm.

Dr Banerjee on the Evolving Multiple Myeloma Treatment Paradigm

August 6th 2024

Rahul Banerjee, MD, FACP, discusses key takeaways from his presentation at an OncLive State of the Science Summit on multiple myeloma.

Dr Hernandez-Ilizaliturri on CAR T-Cell Therapy vs Bispecific Antibodies in DLBCL

August 6th 2024

Francisco Hernandez-Ilizaliturri, MD, discusses deciding between CAR T-cell therapies or approved bispecific antibodies for diffuse large B-cell lymphoma.

Dr Gerds on Unmet Needs in Low-Risk Myelofibrosis

August 6th 2024

Aaron Gerds, MD, discusses clinical implications and areas of unmet need for patients with low- or intermediate-1–risk myelofibrosis.

Dr Vahdat on Recent Data on ADCs in Metastatic TNBC

August 5th 2024

Linda Vahdat, MD, discusses recent antibody-drug conjugate data in metastatic triple-negative breast cancer.

Dr Parikh on the Impact of the ADAURA and ALINA Trials on Early-Stage NSCLC Management

August 5th 2024

Kaushal Parikh, MBBS, discusses how data from the ADAURA and ALINA trials have advanced the management of early-stage non–small cell lung cancer.

Dr Battiwalla on Addressing Unmet Needs in Multiple Myeloma

August 5th 2024

Minoo Battiwalla, MD, discusses remaining unmet needs for patients with multiple myeloma and potential strategies being explored to address these needs.

Dr Bazhenova on Improving Biomarker Development in Lung Cancer

August 5th 2024

Lyudmila A. Bazhenova, MD, discusses steps that the lung cancer field can take to improve biomarker research.

Dr Florez on Addressing Key Gaps in Lung Cancer Care

August 5th 2024

Narjust Florez, MD, discusses the importance of addressing crucial gaps in care for patients with lung cancer.

Association Between Clonal Hematopoiesis, RCC, and Cardiovascular Disease

August 5th 2024

Valisha Shah, MS, discusses the observed association between clonal hematopoiesis and RCC with cardiovascular diseases.

Dr Gadi on Challenges in Identifying HER2-Low Breast Cancer in Community Settings

August 2nd 2024

VK Gadi, MD, PhD, discusses the challenge of identifying patients with HER2-low disease, emphasizing communication between pathologists and medical oncologists in the diagnostic process.

Dr Munir on Cost and QOL Outcomes With Zanubrutinib vs Acalabrutinib in B-Cell Malignancies

August 2nd 2024

Talha Munir, MBChB, PhD, discusses an adverse effect–based economic analysis of zanubrutinib vs acalabrutinib in patients with B-cell malignancies.

Dr Riess on Treatment Developments in ALK+ and ROS1+ NSCLC

August 2nd 2024

Jonathan Wesley Riess, MD, MS, discusses developments in the treatment of patients with NSCLC harboring ALK or ROS1 rearrangements.

Dr Herbst on the Evolution of Targeted Therapies for EGFR+ NSCLC

August 2nd 2024

Roy S. Herbst, MD, PhD, discusses the evolution of targeted therapies in EGFR-mutated NSCLC, as well as hurdles associated with biomarker testing.